摘要:
The present invention concerns compounds of formula (I); in which; - R 2 , R4 and R6, identical or different, represent a hydrogen, chlorine, bromine, iodine or fluorine atom, or an -OH or -O-alkyl group comprising 1 to 6 carbon atoms; -R2 and R4, identical or different, represent a hydrogen atom, or an --OH or -Q-alkyl group comprising 1 to 6 carbon atoms; in which R2' and/or R4' represent(s) a methoxy group; - n is equal to 1, 2 or 3; - X = CH2, G, S or N(R7); and - R7 represents a hydrogen atom or an alkyl group comprising 1 to 6 carbon atoms; and the pharmaceutically acceptable hydrates, solvates and salts thereof.
摘要翻译:本发明涉及式(I)化合物:其中:R 2,R 4和R 6相同或不同,代表氢,氯溴,碘或氟原子,或基团-OH或-O-烷基,包括 1至6个碳原子; R 2'和R 4'相同或不同,表示氢原子或包含1至6个碳原子的基团-OH或-O-烷基; 其中R2'和/或R4'代表甲氧基; n等于1,2,3; X = CH 2,O,S或N(R 7); 并且R 7表示氢原子或含有1至6个碳原子的烷基; 以及其药学上可接受的水合物,溶剂化物和盐。
摘要:
The invention concerns a method for establishing, in vitro , a prognosis of severity in a septic shock patient, comprising the following steps: (i) using a biological sample taken from said patient, measuring, in vitro , the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes, (ii) comparing the level of expression of the expression product of said at least one gene with a control level of expression of the expression product of the same gene indicating a good prognosis of severity, in which a level of expression of the expression product of said at least one gene that is lower than said control level of expression indicates a poor prognosis of severity for the patient, and a kit for implementing the method.
摘要:
The invention relates to a process for determining the susceptibility to nosocomial infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample.
摘要:
The invention relates to an in vitro or ex vivo method for assessing the risk of complication in patients who have suffered an attack or infection resulting in systemic inflammatory response syndrome. The invention is characterized in that it comprises the step of detecting, in a biospecimen collected from said patient, at least one transcript of the IL7R gene, as well as the use of assaying, in vitro or ex vivo , the amount of at least one transcript of the IL7R gene, in a biospecimen collected from a patient who has suffered an attack or infection resulting in systemic inflammatory response syndrome, to assess the risk of complication, and in particular mortality, in said patient. The invention also relates to kits for assaying, in vitro or ex vivo , the amount of at least one transcript of the IL7R gene in a biospecimen.